A5034814958- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Tuberculosis Research and Epidemiology
- Coronary Interventions and Diagnostics
- Telemedicine and Telehealth Implementation
- Lung Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Pharmaceutical Practices and Patient Outcomes
- Clinical practice guidelines implementation
- Pancreatic and Hepatic Oncology Research
- Acute Lymphoblastic Leukemia research
- Cardiac, Anesthesia and Surgical Outcomes
- Lung Cancer Research Studies
- Pharmaceutical Economics and Policy
- Cardiac Imaging and Diagnostics
- Mobile Health and mHealth Applications
- Safe Handling of Antineoplastic Drugs
Ithaca College
2024
Cornell University
2024
Minneapolis Heart Institute Foundation
2024
National University Cancer Institute, Singapore
2020-2023
National University Hospital
2020-2023
National University Health System
2020-2022
National University of Singapore
2020
A dose of 200 mg 3-weekly pembrolizumab was approved by the Food and Drug Administration (FDA) as treatment for advanced non-small cell lung cancer (NSCLC) without oncogenic drivers. This is despite evidence showing no difference in efficacy with 2 mg/kg. Our study aimed to assess a lower fixed 100 mg, which closer mg/kg weight-based an average-sized Asian patient. All patients receiving NSCLC from January 2016 March 2020 National University Hospital, Singapore, were included this...
Background: Telemedicine has demonstrated benefits for cancer patients including the potential to improve care coordination and patient outcomes. Since June 2020, teleconsultations have been implemented in National Cancer Centre Singapore. Objectives: This study aims assess acceptance of telemedicine as a complement traditional in-person identify factors affecting their acceptance. Methods: An online self-administered questionnaire was designed using modified technology model (TAM)...
Chemotherapy is complex. We hypothesized that a design thinking approach could redesign preparatory processes and reduce wait times.A multidisciplinary process mapping exercise was undertaken to understand the current processes, followed by proposing testing solutions. Proposals were selected based on desirability feasibility. These focused starting morning treatments time scheduling pre-made regimens in these slots. The primary outcome measure from appointment treatment. Treatments...
e19385 Background: Pembrolizumab has dramatically improved the survival of patients with non-small cell lung cancer (NSCLC) and is considered standard care for first line treatment NSCLC who do not harbour oncogenic drivers. The fixed dose 200mg was approved by US Food Drug Administration. based on pharmacokinetic analysis. Studies have demonstrated equivalent efficacy weight-based dosing 2mg/kg. An average Asian weighs 50-60kg. We aimed to look at pembrolizumab a low compared dosing....
The rising cost of oncological drugs poses a global challenge to patients, insurers, and policy makers, with the leading worldwide by revenue from immune checkpoint inhibitors (ICIs). Despite its cost, ICI is marked as paradigm shift, offering potential long-term cure. To reduce an attenuated dose based on pharmacological principles can be used while maintaining efficacy. This real-world study aims examine prescribing patterns, effect financial constraints, outcomes in non-small cell lung...